Kalehua Capital Management LLC Makes New Investment in Gossamer Bio, Inc. $GOSS

Kalehua Capital Management LLC purchased a new stake in Gossamer Bio, Inc. (NASDAQ:GOSS) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,236,293 shares of the company’s stock, valued at approximately $3,363,000. Gossamer Bio makes up approximately 2.4% of Kalehua Capital Management LLC’s investment portfolio, making the stock its 15th largest holding. Kalehua Capital Management LLC owned approximately 4.36% of Gossamer Bio at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of GOSS. Tudor Investment Corp ET AL grew its stake in shares of Gossamer Bio by 7.8% during the 3rd quarter. Tudor Investment Corp ET AL now owns 50,103 shares of the company’s stock worth $132,000 after acquiring an additional 3,639 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Gossamer Bio by 24.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 23,964 shares of the company’s stock worth $74,000 after purchasing an additional 4,767 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its position in Gossamer Bio by 22.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company’s stock valued at $82,000 after purchasing an additional 4,771 shares in the last quarter. Deutsche Bank AG lifted its position in Gossamer Bio by 0.4% during the 4th quarter. Deutsche Bank AG now owns 1,284,335 shares of the company’s stock worth $3,981,000 after buying an additional 5,414 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV boosted its stake in shares of Gossamer Bio by 52.3% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock worth $74,000 after buying an additional 8,239 shares during the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Price Performance

NASDAQ:GOSS opened at $0.14 on Monday. The stock’s 50 day moving average price is $0.18 and its two-hundred day moving average price is $0.81. The firm has a market capitalization of $31.92 million, a price-to-earnings ratio of -0.17 and a beta of 2.04. Gossamer Bio, Inc. has a 12-month low of $0.11 and a 12-month high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Friday, May 15th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The firm had revenue of $16.95 million during the quarter, compared to the consensus estimate of $4.67 million. Equities research analysts expect that Gossamer Bio, Inc. will post -0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GOSS shares. HC Wainwright lowered their target price on Gossamer Bio from $5.00 to $2.00 and set a “buy” rating on the stock in a research report on Thursday, June 25th. Weiss Ratings cut Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Gossamer Bio currently has an average rating of “Hold” and a consensus price target of $3.20.

Gossamer Bio Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.